Kane Biotech Inc.

KNE

CA4838092084

Biotechnology & Medical Research

Delayed Toronto S.E. Other stock markets 12:16:44 2024-05-15 pm EDT			5-day change	1st Jan Change
0.135 ^CAD	+8.00%		-3.57%	+68.75%

May. 15	Kane Biotech Expands Wound Care Portfolio with Patented Schultz Biofilm Wound Map	MT
Apr. 18	Transcript : Kane Biotech Inc. - Special Call

Kane Biotech Inc. Announces Resignation of Sarah Prichard as Director

August 18, 2017 at 07:12 am EDT

Kane Biotech Inc. announced that Sarah Prichard has resigned as director of the company.

Latest news about Kane Biotech Inc.

Kane Biotech Expands Wound Care Portfolio with Patented Schultz Biofilm Wound Map	May. 15	MT
Transcript : Kane Biotech Inc. - Special Call	Apr. 18
Kane Biotech Up 12% After Reporting Closing of STEM Animal Health Sale	Apr. 15	MT
Dechra Veterinary Products, Inc. completed the acquisition of 66.66% stake in STEM Animal Health Inc. from Kane Biotech Inc..	Apr. 14	CI
Kane Biotech Agrees to Sell its Interest in STEM Animal Health for US$8 Million	Apr. 11	MT
Transcript : Kane Biotech Inc., Q4 2023 Earnings Call, Mar 26, 2024	Mar. 26
Kane Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Kane Biotech Brief: Says otal revenue for the three months ended December 31, 2023 was $764,997	Mar. 26	MT
Kane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal Health	Mar. 20	MT
Kane Biotech Inc. Appoints Dr. Robert Huizinga as Director and Executive Chair	Feb. 22	CI
Transcript : Kane Biotech Inc. - Shareholder/Analyst Call	Feb. 20
Kane Biotech Inc. Files New Patent on Revyvetm Antimicrobial Wound Gel Spray	Jan. 31	CI
Kane Biotech Announces Correction to Press Release	Dec. 29	MT
Kane Biotech Inc. Announces Amendment to Its Credit Facility	Dec. 28	CI
Kane Biotech Gains 6% As Says To Sell Interest In STEM Animal Health	Dec. 20	MT
Kane Biotech To Sell Interest In STEM Animal Health	Dec. 20	MT
An undisclosed buyer signed a non-binding offer to acquire an unknown stake in STEM Animal Health Inc. from Kane Biotech Inc..	Dec. 19	CI
An undisclosed buyer signed a non-binding offer to acquire an unknown entire stake in STEM Animal Health Inc. from Kane Biotech Inc..	Dec. 19	CI
Transcript : Kane Biotech Inc., Q3 2023 Earnings Call, Nov 28, 2023	Nov. 28
Kane Biotech Third-Quarter Loss Widens Despite Improved Revenue	Nov. 28	MT
Kane Biotech Brief: Loss for Q3 of 2023 was ($1,197,889), an increase of 41% compared to ($851,597) for the quarter ended September 30, 2022	Nov. 28	MT
Kane Biotech Brief: Total revenue for three months ended September 30, 2023 was $717,852, an increase of 26% compared to $571,686 in three months ended September 30, 2022	Nov. 28	MT
Kane Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 28	CI
Kane Biotech Inc. Appoints John Coleman to the Board of Directors	Nov. 16	CI
Kane Biotech Inc. and ProgenaCare Global Launch Newly Rebranded Revyve Antimicrobial Wound Care Fall Forum	Nov. 02	CI

Kane Biotech Inc. is a Canada-based biotechnology company. The Company is engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. It has a portfolio of biotechnologies and products, which includes StrixNB, DispersinB, Aledex, bluestem, bluestem, silkstem, goldstem, coactiv+, coactiv+, DermaKB and DermaKB Biofilm. Its Wound Care & Surgical division is focused on the product development of DispersinB for applications in chronic wound care. Its bluestem product line includes water additives, chews, spray and dental wipes. Its other products in development stage include Coactiv+, antimicrobial wound rinse for use in acute and chronic wounds; Coactiv+, antimicrobial surgical hydrogel for use in surgical and acute wounds, and DispersinB Gel for prosthetic joint infection. It also provides Scalp Detoxifier, Shampoo and Shampoo Bars. Its primary markets for its technologies are animal health and human health.

Sector

Biotechnology & Medical Research

Calendar

2024-05-22 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
KANE BIOTECH INC.	+68.75%	13.08M
MODERNA, INC.	+29.77%	49.46B
IQVIA HOLDINGS INC.	+1.00%	42.58B
LONZA GROUP AG	+49.84%	42.49B
CELLTRION, INC.	-5.26%	29.09B
ICON PUBLIC LIMITED COMPANY	+13.68%	26.61B
ALNYLAM PHARMACEUTICALS, INC.	-22.99%	18.64B
BIO-TECHNE CORPORATION	+8.22%	13.16B
MEDPACE HOLDINGS, INC.	+32.41%	12.55B
UNITED THERAPEUTICS CORPORATION	+24.01%	12.1B

Other Biotechnology & Medical Research

Kane Biotech Inc.

Equities

KNE

CA4838092084

Biotechnology & Medical Research

Kane Biotech Inc. Announces Resignation of Sarah Prichard as Director

Latest news about Kane Biotech Inc.

Chart Kane Biotech Inc.

Company Profile

Income Statement Evolution

Sector Other Biotechnology & Medical Research